John Parkinson

This regulatory review is for the prevention of recurrent vaginal yeast infections. And if approved, it would be a second indication for the antifungal related to these infections.

Public health officials made the decision after seeing increasing incidence rates.

Working to Fight AMR is working in Washington DC to help pass policies in Congress to help alleviate this significant issue.

He is experiencing mild symptoms and is going to take Paxlovid.

This decision follows votes to allow the vaccine to be indicated for prevention of the virus in adults 18 years and older.

A specific immunization marker showed the percentage of children receiving common vaccines fell 5% between 2019 and 2021.

Federal government agencies offer a best practices approach for testing, announce more laboratories are testing for the virus and provide insights on vaccines and therapies.

The European agency says there have been “a few cases of anaphylaxis.” The label will also include warnings for paraesthesia and hypoaesthesia.

There has been an increase in transmission rates, the release of new White House strategies to address BA.5, and new potential offerings to prevent and treat the virus.

The company’s investigational mRNA-1273.214 vaccine has now demonstrated significantly higher antibody titers against all tested variants.

The CDC announces both the Mayo Clinic and Labcorp begin testing for the virus.

The federal agency linked Big Olaf Creamery ice cream to the recent outbreak in Florida.

Research shows specific climate elements affect mosquito proliferation and can play a role in predictors of vector activity and insect control interventions.

Here is a rundown of the most popular and significant stories we covered this past week.

The federal agency has reported 1 death and 22 hospitalizations stemming back to January of 2021.

The submission is based off both non-clinical and clinical data, including results from the phase 2/3 EPIC-HR study.

Emergency medicine physicians are leaving behind their emergency rooms and opening primary care practices, which does not necessarily translate to a smooth transition with some inherent challenges associated with training and expectations.

With the impending start to the 2022-2023 influenza season just a few months away, here is some information on what is being studied for vaccines as well as recommendations and new testing.

The investigational therapy’s data points to a path towards a potential functional cure.

Rochelle P. Walensky, MD, MPH, signs off on the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) recommendation for individuals 6 through 17 years of age.

The federal agency says this is one of the worst outbreaks of this disease among these groups in US history, and has public health officials concerned as people gather during ongoing Pride Month activities.

The company’s 15-valent conjugate shot becomes the first one that is approved in nearly a decade.

Studies, advances, and authorizations continue in this paramount area within infectious disease.

The CDC director endorsed the vote, and vaccines could be available to this young pediatric population by later this week.

The committee voted twice splitting the questions into younger children (6-11 years) and adolescent (12-17 years) cohorts due to different vaccine dosing amounts.

Aethlon Medical’s proprietary Hemopurifier is being studied to treat COVID-19, and they recently reported results.

The start of Men’s Health Week offers an opportunity for men to get screened for a variety of health issues and be proactive with their health including those who might be at risk of HIV and may benefit from PrEP.

Data results from its phase 3 trial showed it was statistically significant and the company plans to follow-up with regulatory bodies later this year.

Tecovirimat (Tpoxx) is an antiviral agent that is already indicated for another orthopoxvirus, smallpox. And studies are ongoing to see if it has potential efficacy in treating monkeypox.

The vote was 21-0 in favor of an emergency use authorization (EUA), with one voter abstaining.